---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-048593"
form_type: "8-K"
ticker: "CCCC"
cik: "0001662579"
company_name: "C4 Therapeutics, Inc."
filed_at: "2024-11-20T23:59:59+00:00"
generated_at: "2026-05-29T21:53:30.969984+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# C4 Therapeutics appoints Steve Hoerter, former Deciphera CEO, to board of directors

## Summary
- Steven L. Hoerter appointed as Class II director effective November 19, 2024; serves until 2025 annual meeting.
- Hoerter has over 30 years of oncology leadership; was CEO of Deciphera (acquired by ONO for $2.4B).
- Granted 65,000 stock options under 2020 Plan; vests 1/3 on first anniversary, remainder quarterly over 2 years.
- Board determined Hoerter independent per Nasdaq standards; brings commercialization expertise to guide pipeline.
- Hoerter also serves on ORIC Pharmaceuticals board; previously led QINLOCK and TIBSOVO launches.

## SEC filing metadata
- accession: 0001628280-24-048593
- form_type: 8-K
- ticker: CCCC
- cik: 0001662579
- company_name: C4 Therapeutics, Inc.
- filed_at: 2024-11-20T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662579/000162828024048593/0001628280-24-048593-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662579/000162828024048593/cccc-20241120.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-048593
- JSON: https://secwatch.observer/filing/0001628280-24-048593.json
- Plain text: https://secwatch.observer/filing/0001628280-24-048593.txt

## Key facts
- Executive change
  Steven L. Hoerter was appointed as Director at C4 Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On November 19 , 2024 , the Board of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Steven L. Hoerter as a director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662579/000162828024048593/0001628280-24-048593-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.